Evercore ISI Group Maintains Outperform on AbbVie, Lowers Price Target to $235

Benzinga Newsdesk www.benzinga.com Negative 94.9%

Neg 94.9% Neu 0% Pos 0%

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $236 to $235.